New molecular methods for improved early detection of cancer

The Dieter Morszeck Foundation supports the Junior Clinical Cooperation Unit (KKE) “Multiparametric Methods for the Early Detection of Prostate Cancer” at the DKFZ. The group is headed by Dr. Magdalena Görtz, who focuses on the personalized early detection of prostate and breast cancer.

The early detection of tissue changes and precancerous stages is crucial for patients’ chances of recovery. As the number of new cases is set to rise in the coming years, early detection of cancer is becoming increasingly important. The understanding of the molecular properties of tumors and the rapid development of new technologies to detect small amounts of mutated genetic material in the blood (liquid biopsies) open up the possibility of completely new early detection tests. These tests must be combined with established medical examinations, imaging and endoscopy in order to find potential tumors at an early stage.

The main focus of the junior research group is on the implementation of molecular methods in conjunction with state-of-the-art imaging. The group is working on the development of more precise prediction models, the further development of less invasive diagnostic procedures and improved risk assessment in the early detection of prostate cancer. In addition, the team is investigating the quality of diffusion-weighted, non-contrast breast magnetic resonance imaging (MRI) for gynecological imaging and screening to assess its potential as an improvement or replacement for conventional mammography screening.

Early detection of prostate cancer plays a crucial role, as the aggressiveness and progression of this disease can vary greatly. In a recent interview, Dr. Magdalena Görtz emphasized the need for an individualized approach to effectively deal with the diversity of prostate cancer. The prostate specific antigen (PSA) biomarker is often used for early detection, but it can also be elevated in benign prostate enlargement, which can lead to unnecessary invasive diagnoses. The main goal is to detect aggressive tumors early and treat them adequately, while reducing avoidable invasive procedures.

In this article, you will learn more about the goals for optimal early detection of prostate cancer, including efforts to optimize non-invasive diagnostics and develop personalized screening programs. Learn how the aggressiveness of prostate cancer can be better predicted using innovative methods to enable personalized diagnosis and treatment planning.

Would you like to delve deeper into the topic and gain first-hand insights from the expert? Watch the full interview now!